In this three-part series of discussions with top experts in clinical development for rare disease and orphan indications, Medpace, along with industry partners, will address some of the key challenges, opportunities, and considerations for conducting research in this dynamic and complex area of research.
Read More
In Part 1 of a 3 part blog series, we will explore how the heritability of neurological diseases and psychiatric diseases is changing the clinical development landscape. From there, we will take a look at new genetic findings in a number of different diseases and how these findings are making us rethink our broad view of how we ought to approach these diseases. Finally, we will explore the history of treatment of rare diseases with CNS manifestations, touching on both successes and failures.
Read More
Patient-centricity is becoming increasingly important in all areas, but particularly in rare diseases. In this post, Dr. Richard Scheyer discusses the importance of patient-centricity in rare disease studies.
Read More
In this post, Dr. Terence Eagleton highlights the growing interest in the development of products in the rare disease space, the unique challenges involved, and strategies for leveraging rare disease research networks to accelerate drug development.
Read More